Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: Determination of the maximum-tolerated dose of ProMACE-CytaBOM

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1275-1281

  Gordon, L I ^a   Anderson, J ^a   Habermann, T M ^a   Winter, J N ^a   Glick, J ^a   Schilder, R J ^a   Cassileth, P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; LYMPHOMA; MALE; MAXIMUM ALLOWABLE CONCENTRATION; ORAL DRUG ADMINISTRATION; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029915309     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1275     Document Type: Article

References (13)

1. Armitage JO: Treatment of non-Hodgkin's lymphoma. New Engl J Med 328:1023-1030, 1992
2. Elias L, Portlock CS, Rosenberg SA: Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, Adriamycin, vincristine and prednisone (CHOP). Cancer 42:1705-1710, 1978
3. Shipp MA: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has 'high- risk' disease? Blood 83:1165-1173, 1994
4. Gordon LI, Harrington D, Andersen J, et al: Comparison of a second-generation regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. New Engl J Med 327:1342-1349, 1992
5. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl J Med 328:1002-1006, 1993
6. Skipper HE: Dose intensity versus total dose of chemotherapy: An experimental basis, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lipincott, 1990, pp 43-64
7. Frei E III, Canellos GP: Dose: A critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980
8. Hryniuk W, Bush H: The importance of dose-intensity chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
9. Meyer RM, Hryniuk WM, Goodyear MD: The role of dose-intensity in determining outcome in intermediate grade non-Hodgkin's lymphoma. J Clin Oncol 9:339-347, 1991
10. DeVita VT Jr, Hubbard SM, Longo DL: The chemotherapy of lymphomas: Looking back, moving forward. The Richard and Hilda Rosenthaal Foundation Award lecture. Cancer Res 47:5810-5824, 1987
11. Kwak LW, Halpern J, Olshen RA, et al: Prognostic significance of actual dose-intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 8:963-977, 1990
12. Meyer RM, Quirt IC, Skillings JR, et al: Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. New Engl J Med 329:1770-1776, 1993
13. The non-Hodgkin's lymphoma pathologic classification project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage. Cancer 49:2112-2135, 1982